Standout Papers

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer 2016 2026 2019 2022 6.9k
  1. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer (2016)
    Martin Reck, Delvys Rodríguez‐Abreu et al. New England Journal of Medicine
  2. Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial (2017)
    Jean‐Sébastien Frenel, Christophe Le Tourneau et al. Journal of Clinical Oncology

Immediate Impact

6 by Nobel laureates 6 from Science/Nature 72 standout
Sub-graph 1 of 20

Citing Papers

Therapy-induced senescent cancer cells contribute to cancer progression by promoting ribophorin 1-dependent PD-L1 upregulation
2025 Standout
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
2023 Standout
3 intermediate papers

Works of Reshma Rangwala being referenced

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 Standout

Author Peers

Author Last Decade Papers Cites
Reshma Rangwala 6851 4324 1768 40 8.9k
Tibor Csőszi 8820 5714 1883 81 10.4k
Yue Shentu 10488 6838 2446 34 12.3k
Michael Smylie 7094 4305 1587 92 8.9k
Suman Rao 7746 5248 1763 21 9.0k
Marisa Dolled‐Filhart 7920 4746 1898 69 11.0k
Ali Tafreshi 8696 6016 1901 92 11.3k
Andrea Fülöp 7689 5187 1758 14 8.9k
Craig Devoe 10194 3874 4442 45 12.5k
Gregory M. Lubiniecki 11987 7988 2782 55 13.9k
Marcin Kowanetz 9158 5621 2548 106 11.9k

All Works

Loading papers...

Rankless by CCL
2026